Skip to main content
. 2020 Jan 14;11:259. doi: 10.1038/s41467-019-13689-y

Fig. 2. Type I IFN signature and high apoptotic primed state coincide with breast tumor ex vivo sensitivity to paclitaxel.

Fig. 2

a, b Apoptotic index in 163 fresh human breast tumors defined by the % of active caspase-3 positive tumor cells detected by IHC after 48 h ex vivo paclitaxel (left) or ABT-737 (right) treatments separately (a) and co-response (b). c, d Tumor Ki-67 index (%) in 56 ABT-737 sensitive tumors (above 20% of active caspase-3 positive tumor cells) related to the % of active caspase-3 positive tumor after paclitaxel treatment c or related to paclitaxel sensitivity/resistance (20% apoptotic index threshold) (d). e Comparison of gene expression signatures between both paclitaxel resistant and paclitaxel sensitive tumor groups (60 classified tumors based on their ex vivo paclitaxel sensitivity). f STAT1, type I IFN and proliferation scores obtained from the transcriptome. g IFNα quantification in supernatants of tumor slices treated or not with paclitaxel. n = 5 sensitive tumors and n = 6 resistant tumors. Error bars indicate mean +/− SEM; Two-sided unpaired (d, f) and paired (g) t-test. The symbols correspond to a p-value inferior to *0.05 and **0.01. NS: not significant.